SX-682

SX-682 is an orally bioavailable, potent allosteric inhibitor of CXCR1 and CXCR2. SX-682 can block tumor myeloid-derived suppressor cells (MDSCs) recruitment and enhance T cell activation and antitumor immunity[1].

Product Specifications

CAS Number

[1648843-04-2]

Product Name Alternative

(±)-Ibuprofen (L-lysine)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

CXCR

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology; Endocrinology

Assay Protocol

https://www.medchemexpress.com/sx-682.html

Purity

99.67

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC=C(F)C=C1)C(C=N2)=CN=C2SCC3=CC(OC(F)(F)F)=CC=C3B(O)O

Molecular Formula

C19H14BF4N3O4S

Molecular Weight

467.20

Precautions

H302, H315, H319, H335

References & Citations

[1]Sun L, et al. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. JCI Insight. 2019 Apr 4;4 (7) .|[2]Lu X, et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 2017 Mar 30;543 (7647) :728-732.